Because BRCA1&2 gene mutation carriers have a high risk of developing early-onset breast and ovarian cancer during their lifetime, the aim of this study is to determine whether plasma telomeric cfDNA level is associated with the BRCA1&2 mutations. The gene discussed is BRCA1; the disease is ovarian carcinoma.